- Mr. Botero brings nearly two decades of domestic and
international operational experience with industry giant Philip
Morris International, most recently as Director of Operations for
the Andean Cluster
- The appointment will help drive the growth of the Company's
production capacity as it readies to feed global supply
channels
RIONEGRO, Colombia,
July 22, 2019 /CNW/ - PharmaCielo
Colombia Holdings S.A.S. ("PharmaCielo Colombia" or the
"Company"), the premier cultivator and producer of medicinal-grade
cannabis oils and extracts in Colombia and subsidiary of Canadian firm
PharmaCielo Ltd. (TSXV:PCLO, OTC:PHCEF), is pleased
to announce the appointment of Andres
Felipe Botero as Chief Operations Officer (COO).
As PharmaCielo Colombia evolves from the initial founding stage
into a mature, large-scale cultivator and international provider of
high-grade cannabis oils, Mr. Botero will be responsible to manage
this transition successfully. As the new COO, Mr. Botero will
oversee the Company's operations across the entire production
spectrum from cultivation to end-product, ensuring seamless
integration and production capacity growth.
David Attard, Chief Executive
Officer of PharmaCielo Ltd., stated, "The addition of Mr.
Botero to PharmaCielo Colombia's executive team is another step to
solidify our position as a premier provider of medicinal oils and
extracts to international markets. Mr. Botero's extensive
experience in managing, streamlining and growing production
capacity on a global scale will be a great asset to the Company and
our business partners."
Mr. Botero brings nearly two decades of experience in leading
domestic and international operations with Philip Morris
International, most recently as the Director of Operations for the
Andean Cluster, overseeing cultivation, manufacturing, quality
assurance, supply chain and distribution. Previously, he
spearheaded Philip Morris International's operations for the launch
of its reduced risk product in Colombia. Before returning to Colombia, Mr. Botero also managed the
operations of a global product portfolio from the company's Swiss
headquarters and led other projects for the company in Greece. Mr. Botero holds a Mechanical
Engineering degree from EAFIT University.
Andres Botero,
PharmaCielo Colombia COO, expressed enthusiasm about
the appointment. "I am very excited about the opportunity to join
PharmaCielo Colombia and lend my expertise in helping to drive the
Company's growth forward. As a Colombian, it also gives me great
pride to join a company and an industry that have been leading
great positive change and making valuable/significant contributions
to the country's economy and social
fabric."
Mr. Botero is assuming the operational responsibilities of
Federico Cock-Correa, one of
PharmaCielo's co-founders, who will now act as a director of
PharmaCielo Colombia and advisor to the Company, maintaining
the high level relationships with government he has developed,
while also leveraging his over 30 years' experience and
industry network in providing invaluable support for the business
growth of PharmaCielo Colombia.
"As a co-founder of the company, Federico's contribution to date
has been an essential one, without which we would not have the
recognition for global leadership we currently hold," stated
Andres Botero. "I look forward to
the opportunity to work with him directly and to his continued
contributions in increasing our focus on marketing and sales within
Colombia and beyond."
About PharmaCielo
PharmaCielo Ltd. (TSXV:PCLO, OTC: PHCEF) is a global company,
headquartered in Canada, with a
focus on ethical and sustainable processing and supplying of all
natural, medicinal-grade cannabis oil extracts and related products
to large channel distributors. PharmaCielo's principal (and wholly
owned) subsidiary is PharmaCielo Colombia Holdings S.A.S.,
headquartered at its nursery and propagation centre located in
Rionegro, Colombia.
The boards of directors and executive teams of both PharmaCielo
and PharmaCielo Colombia Holdings are comprised of a diversely
talented group of international business executives and specialists
with relevant and varied expertise. PharmaCielo recognized the
significant role that Colombia's
ideal location will play in building a sustainable business in the
medical cannabis industry, and the Company, together with its
directors and executives, is executing on a business plan focused
on supplying the international marketplace.
Forward-Looking Statements
This press release may contain forward-looking statements.
Forward-looking statements can be identified by the use of words
such as, "expects", "is expected", "intends", "believes", or
variations of such words and phrases or state that certain actions,
events or results "may" or "will" be taken, occur or be achieved.
Forward-looking statements are based on assumptions, including with
respect to PharmaCielo's planned products, and the ability to
execute its business plan that management believes are reasonable
in the circumstances, but the actual results, performance or
achievements of PharmaCielo's business may be materially different
from any future results, performance or achievements expressed or
implied by any forward-looking statements. Forward-looking
statements can be affected by known and unknown risks,
uncertainties and other factors, including, but not limited to, the
equity markets generally, risks associated with early-stage
companies, risks associated with the regulation of cannabis and
cannabinoid derivatives, failure to obtain necessary TSXV approval,
competition for PharmaCielo's planned products, risks associated
with operating in Colombia, and
currency exchange risk. Accordingly, readers should not place undue
reliance on forward-looking statements.
Except as required by law, PharmaCielo undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
SOURCE PharmaCielo Ltd.